Using a targeted metabolomics approach to explore differences in ARDS associated with COVID-19 compared to ARDS caused by H1N1 influenza and bacterial pneumonia

Chel Hee Lee,Mohammad M. Banoei,Mariam Ansari,Matthew P. Cheng,Francois Lamontagne,Donald Griesdale,David E. Lasry,Koray Demir,Vinay Dhingra,Karen C. Tran,Terry Lee,Kevin Burns,David Sweet,John Marshall,Arthur Slutsky,Srinivas Murthy,Joel Singer,David M. Patrick,Todd C. Lee,John H. Boyd,Keith R. Walley,Robert Fowler,Greg Haljan,Donald C. Vinh,Alison Mcgeer,David Maslove,Puneet Mann,Kathryn Donohoe,Geraldine Hernandez,Genevieve Rocheleau,Uriel Trahtemberg,Anand Kumar,Ma Lou,Claudia dos Santos,Andrew Baker,James A. Russell,Brent W. Winston,J. A. Russell,K. R. Walley,J. Boyd,T. Lee,J. Singer,D. Sweet,K. Tran,S. Reynolds,G. Haljan,M. Cheng,D. Vinh,T. Lee,F. Lamontagne,B. Winston,O. Rewa,J. Marshall,A. Slutsky,A. McGeer,V. Sivanantham,R. Fowler,D. Maslove,S. Perez Patrigeon,K. D. Burns,for the *ARBs CORONA I. Investigators
DOI: https://doi.org/10.1186/s13054-024-04843-0
IF: 15.1
2024-02-29
Critical Care
Abstract:Acute respiratory distress syndrome (ARDS) is a life-threatening critical care syndrome commonly associated with infections such as COVID-19, influenza, and bacterial pneumonia. Ongoing research aims to improve our understanding of ARDS, including its molecular mechanisms, individualized treatment options, and potential interventions to reduce inflammation and promote lung repair.
critical care medicine
What problem does this paper attempt to address?
### Problems the paper attempts to solve This paper aims to explore the differences in metabolic phenotypes of acute respiratory distress syndrome (ARDS) caused by different pathogens (such as COVID - 19, H1N1 influenza and bacterial pneumonia) through targeted metabolomics methods. Specifically, the main objectives of the study are: 1. **Compare the metabolic phenotypes of ARDS caused by different infectious causes**: Researchers hope to better understand the metabolic pathways and pathological mechanisms behind these diseases by comparing the metabolic characteristics of ARDS patients caused by different etiologies (such as COVID - 19, H1N1 and bacterial pneumonia). 2. **Reveal the metabolic differences between ARDS caused by COVID - 19 and other types of ARDS**: Researchers are particularly interested in the metabolic differences between ARDS caused by COVID - 19 (C19/A), ARDS caused by H1N1 (H1N1/A) and ARDS caused by bacterial pneumonia (PNA/A), in the hope of finding unique metabolic markers. 3. **Evaluate the severity of illness in COVID - 19 patients**: The study also attempts to identify metabolic changes related to the severity of illness by comparing COVID - 19 ARDS patients (C19/A) who require ICU treatment with COVID - 19 pneumonia patients (C19/P) who do not require ICU treatment. 4. **Propose a bedside formula for the early diagnosis and evaluation of COVID - 19 ARDS**: By identifying key metabolites associated with ARDS of different etiologies, researchers hope to develop a simple and effective bedside formula for the early diagnosis of COVID - 19 ARDS and the evaluation of its severity. ### Overview of methods To achieve the above - mentioned goals, researchers used quantitative liquid chromatography - tandem mass spectrometry (LC - MS/MS) and direct injection tandem mass spectrometry (DI - MS/MS) platforms to conduct targeted metabolomics analysis on plasma samples from 150 patients. These patients include: - ARDS patients caused by COVID - 19 (C19/A) - ARDS patients caused by H1N1 (H1N1/A) - ARDS patients caused by bacterial pneumonia (PNA/A) - COVID - 19 - infected patients without ARDS (C19/P) - ICU mechanical ventilation control group (CTL) Through the metabolomics analysis of these samples, researchers hope to find specific metabolic markers that can distinguish ARDS of different etiologies and provide new ideas for clinical diagnosis and treatment. ### Main findings The research results show that there are indeed significant metabolic differences among ARDS patients caused by different etiologies. For example, ARDS caused by COVID - 19 and ARDS caused by H1N1 show differences in metabolic pathways such as taurine, hypotaurine, pyruvate, tricarboxylic acid cycle metabolites, lysine and glycerophospholipids. In addition, the study also found metabolic changes related to the severity of illness, which provide potential biomarkers for early diagnosis and evaluation. In general, this study, through detailed metabolomics analysis, reveals the unique metabolic characteristics of ARDS of different etiologies, providing important scientific basis for further understanding the pathological mechanisms of ARDS and developing targeted treatment strategies.